There's no question that Moderna(NASDAQ: MRNA) is about to have a very good year financially. The biotech has major supply deals lined up for its COVID-19 vaccine and is hard at work cranking out millions of doses. But what are Moderna's long-term prospects? In this Motley Fool Live video recorded on Feb. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how Moderna might fare going forward.

毫无疑问，Moderna在财务上将会有一个非常好的一年。该生物技术公司的COVID-19疫苗有大量供货协议，正在努力生产数百万剂疫苗。但Moderna的长期前景如何?在这段2021年2月10日录制的直播视频中，撰稿人Keith Speights和Brian Orelli讨论了Moderna将如何发展。

10 stocks we like better than Moderna Inc.

我们比Moderna公司更喜欢的10只股票。

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

大卫和汤姆刚刚透露了他们认为目前投资者最值得购买的十支股票。摩登纳公司不在其中!没错，他们认为这10只股票更值得买进。

Keith Speights: Moderna long-term view. The ticker there is MRNA. What's your quick thoughts on the long-term prospects for Moderna?

Keith Speights:现代的长期观点。这里的标记是MRNA。你对Moderna的长远前景有什么看法?

Brian Orelli: Moderna has great long-term prospects, whether it justifies the $71 billion market cap is debatable. Biogen has many drugs on the market, and they are at 41 billion. Regeneron has many drugs on the market and they are at 52 billion. Moderna's at 71 billion and they have one drug on the market.

Brian Orelli: Moderna拥有良好的长期发展前景，但它是否能证明710亿美元的市值是合理的还有待商榷。百健公司在市场上有很多药物，它们的价格是410亿美元。Regeneron在市场上有很多药物，价值520亿美元。Moderna的价格是710亿美元他们只有一种药在市场上销售。

We don't really know exactly how long those sales are going to last, whether there's going to be one-off sales or whether we're going to have to keep getting vaccinated every year. I like Moderna's pipeline. I like their technology, it's definitely proven out. But I have a hard time seeing $71 billion worth of value in the pipeline.

我们真的不知道这些销售会持续多久，是否会有一次性的销售，或者我们是否要继续每年接种疫苗。我喜欢Moderna的管道。我喜欢他们的技术，绝对是经过验证的。但我很难看到710亿美元的价值正在酝酿之中。

Speights: You and I have had this discussion before. If you're going to invest in Moderna, you need to be a long-term investor because over the long run, the company could roll out plenty of other mRNA therapies and vaccines and be a big winner. Over the short run, it probably doesn't have enough catalysts to cause the stock to jump a whole lot more over the next year or so.

斯贝茨:你和我以前讨论过这个问题。如果你打算投资Moderna，你需要做一个长期投资者，因为从长远来看，该公司可能推出大量其他mRNA疗法和疫苗，成为大赢家。在短期内，它可能没有足够的催化剂来促使股价在未来一年左右的时间里大幅上涨。

Orelli: Even a double from here is a $140 billion mark up [laughs]. Are we getting to the size of Pfizer [laughs] at that point? Let me look at Pfizer's.

奥雷利:即使是这个数字的两倍，也要增加1400亿美元(笑)。到那时，我们会达到辉瑞(笑)的规模吗?让我们来看看辉瑞制药。

Speights: Pfizer is over 200 billion market cap, right?

斯贝茨:辉瑞的市值超过2000亿美元，对吧?

Orelli: Yeah, has a 193.

是的，有193个。

Speights: Okay.

Speights:好的。

Orelli: A triple from here gets you to the size of Pfizer. That feels like a stretch considering how long Pfizer has been around. To get to the size of a Pfizer in a decade still feels even a little much. I feel like the valuations are really high right now. I'd much rather own other biotech companies that are smaller and have more catalysts to see how they can get from point A to point B in valuation.

从这里算起，三倍就相当于辉瑞制药的规模。考虑到辉瑞已经存在了这么久，这感觉有点牵强。要在十年内达到辉瑞制药的规模，仍然感觉有点多。我觉得现在的估值真的很高。我更愿意持有其他规模较小、拥有更多催化剂的生物技术公司，看看它们如何将估值从A点提升到B点。

Speights: Even when Moderna was at a 30-40 billion market cap, I thought, OK, you could argue that it's overpriced, but their platform potential, I could see that. But you're right, at $70 billion market cap, you really start to wonder how much more room this stock is going to have to run at least over the next couple of years or so.

斯贝茨:即使当Moderna的市值达到300 - 400亿美元时，我想，好吧，你可能会说它的定价过高，但我能看到他们平台的潜力。但你是对的，以700亿美元的市值，你真的开始怀疑至少在接下来的几年里，这只股票还能有多大的运行空间。

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of Pfizer. The Motley Fool recommends Biogen and Moderna Inc. The Motley Fool has a disclosure policy.

布莱恩·奥雷利博士在上述股票中没有任何职位。Keith Speights拥有辉瑞公司的股份。《杂色傻瓜》推荐Biogen and Moderna公司的产品。《斑驳的傻瓜》有个披露政策。